Carl Dambkowski sells APGE shares under 10b5-1

Carl Dambkowski reported Form 144 filings disclosing sales of Common Stock.

Rhea-AI Filing Summary

Carl Dambkowski reported Form 144 filings disclosing sales of Common Stock. The filing lists 10b5-1 sales of 26,400 shares on 06/22/2026 for $3,500,574.00, 5,500 shares on 06/03/2026 for $432,905.00, and 5,500 shares on 05/06/2026 for $462,768.35.

The excerpt also shows securities to be sold tied to an exercise of stock options of 12,375 shares dated 07/01/2026 and 4,125 Restricted Stock Awards dated 12/14/2022.

Insights

Corporate Governance Analyst

Form 144 lists scheduled 10b5-1 sales and planned option-derived dispositions.

The filing documents three 10b5-1 dispositions: $3,500,574.00 for 26,400 shares on 06/22/2026, and two earlier 10b5-1 sales of 5,500 shares each on 06/03/2026 and 05/06/2026 with proceeds shown. It separately lists 12,375 shares tied to an exercise of stock options dated 07/01/2026 and 4,125 Restricted Stock Awards dated 12/14/2022.

These items are procedural disclosures of transactions under a Rule 10b5-1 plan and option exercises. Cash treatment for the option exercise and any post-transaction holdings are not provided in the excerpt; subsequent regulatory filings will show final position details.

Key Figures

10b5-1 sale (06/22/2026): 26,400 shares 10b5-1 sale (06/03/2026): 5,500 shares 10b5-1 sale (05/06/2026): 5,500 shares +2 more

5 metrics

10b5-1 sale (06/22/2026) 26,400 shares Proceeds <money>$3,500,574.00</money>

10b5-1 sale (06/03/2026) 5,500 shares Proceeds <money>$432,905.00</money>

10b5-1 sale (05/06/2026) 5,500 shares Proceeds <money>$462,768.35</money>

Exercise of Stock Options listed 12,375 shares Dated <date>07/01/2026</date>

Restricted Stock Awards listed 4,125 shares Dated <date>12/14/2022</date>

Key Terms

10b5-1 sales, Restricted Stock Awards, Exercise of Stock Options

3 terms

10b5-1 sales regulatory

"10b5-1 Sales for CARL DAMBKOWSKI 221 Crescent St."

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

Restricted Stock Awards financial

"Restricted Stock Awards | Issuer | | | 4125 | 12/14/2022"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

Exercise of Stock Options financial

"Exercise of Stock Options | Issuer | | | 12375 | 07/01/2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What 10b5-1 sales did APGE insider Carl Dambkowski report?

He reported three 10b5-1 sales: 26,400 shares on 06/22/2026 for $3,500,574.00, and 5,500 shares on 06/03/2026 and 5,500 shares on 05/06/2026 with proceeds shown in the filing.

Does the filing show planned option-related sales for APGE (symbol APGE)?

Yes. The excerpt lists an exercise of stock options for 12,375 shares dated 07/01/2026, shown under "Securities To Be Sold" in the filing excerpt.

How many Restricted Stock Awards are noted in the APGE Form 144 excerpt?

The filing shows 4,125 Restricted Stock Awards dated 12/14/2022 listed under "Securities To Be Sold" in the provided excerpt.

Do the proceeds listed in the filing indicate cash received by the insider or company for APGE?

The filing reports proceeds amounts for each 10b5-1 sale (e.g., $3,500,574.00 for 26,400 shares); the excerpt does not state who receives the cash beyond the transaction entries.

Are the 10b5-1 sales in the filing routine or discretionary for APGE insider activity?

The trades are labeled as 10b5-1 sales in the excerpt, indicating they were executed under pre-arranged trading plans; the filing text itself supplies the trade dates, share counts, and proceeds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 05:00 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001983476
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	APOGEE THERAPEUTICS INC
SEC File Number	001-41740
Address of Issuer	221 Crescent St., Building 17 Suite 102b Waltham MASSACHUSETTS 02453
Phone	6503945230
Name of Person for Whose Account the Securities are To Be Sold	CARL DAMBKOWSKI
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	16500	2190045.00	61902733	07/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/01/2026	Exercise of Stock Options	Issuer			12375	07/01/2026	Cash
Common	12/14/2022	Restricted Stock Awards	Issuer			4125	12/14/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for CARL DAMBKOWSKI 221 Crescent St., Building 17 Suite 102b Waltham MA 02453	Common	06/22/2026	26400	3500574.00
10b5-1 Sales for CARL DAMBKOWSKI 221 Crescent St., Building 17 Suite 102b Waltham MA 02453	Common	06/03/2026	5500	432905.00
10b5-1 Sales for CARL DAMBKOWSKI 221 Crescent St., Building 17 Suite 102b Waltham MA 02453	Common	05/06/2026	5500	462768.35

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	07/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/22/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Carl Dambkowski
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)